T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from lymphoblasts of T-cell origin. While TALL accounts for only 15% of childhood and 25% of adult ALL, 30% of patients relapse with a poor outcome. Targeted therapy of resistant and high-risk pediatric T-ALL is therefore urgently needed, together with precision medicine tools allowing the testing of efficacy in patient samples. Furthermore, leukemic cell heterogeneity requires drug response assessment at the single-cell level. Here we used single-cell mass cytometry to study signal transduction pathways such as JAK-STAT, PI3K-AKT-mTOR and MEK-ERK in 16 diagnostic and five relapsed T-ALL primary samples, and investigated the in vitro response of cells to Interleukin-7 (IL-7) and the inhibitor BEZ-235. T-ALL cells showed upregulated activity of the PI3K-AKT-mTOR and MEK-ERK pathways and increased expression of proliferation and translation markers. We found that perturbation induced by the ex vivo administration of either IL-7 or BEZ-235 reveals a high degree of exclusivity with respect to the phospho-protein responsiveness to these agents. Notably, these response signatures were maintained from diagnosis to relapse in individual patients. In conclusion, we demonstrated the power of mass cytometry single-cell profiling of signal transduction pathways in T-ALL. Taking advantage of this advanced approach, we were able to identify distinct clusters with different responsiveness to IL-7 and BEZ-235 that can persist at relapse. Collectively our observations can contribute to a better understanding of the complex signaling network governing T-ALL behavior and its correlation with influence on the response to therapy.

Childhood Leukaemia Investigation Prague Czech Republic; Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University Prague Czech Republic

Fondazione Tettamanti Clinica Pediatrica Università degli Studi Milano Bicocca Monza Italy

German Rheumatism Research Center Berlin a Leibniz Institute Berlin Germany

Pediatric Hematology Oncology and Stem Cell Transplant Division Women and Child Health Department University of Padova Padova Italy

See more in PubMed

Pui CH. Acute lymphoblastic leukemia: introduction. Semin Hematol. 2009;46(1):1-2. PubMed PMC

Girardi T, Vicente C, Cools J, Keersmaecker K De. The genetics and molecular biology of T-ALL. Blood. 2017;129(9):1113-1123. PubMed PMC

Klumper E, Pieters R, Veerman A, et al. . In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 1995;86(10):3861-3868. PubMed

Gao J, Liu WJ. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. Eur Rev Med Pharmacol Sci. 2018;22(22):7858-7866. PubMed

Lauten M, Moricke A, Beier R, et al. . Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012;97(7):1048-1056. PubMed PMC

Follini E, Marchesini M, Roti G. Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2019;20(12):3021. PubMed PMC

Scheijen B. Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies. Cancer Drug Resist. 2019;2:647-664. PubMed PMC

De Smedt R, Morscio J, Goossens S, Van Vlierberghe P. Targeting steroid resistance in T-cell acute lymphoblastic leukemia. Blood Rev. 2019;38:100591. PubMed

Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med. 1993;177(2):305-316. PubMed PMC

Lindqvist CM, Lundmark A, Nordlund J, et al. . Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget. 2016;7(39):64071-64088. PubMed PMC

Abraham N, Ma MC, Snow JW, Miners MJ, Herndier BG, Goldsmith MA. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene. 2005;24(33):5252-5257. PubMed

Silva A, Laranjeira ABA, Martins LR, et al. . IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011;71(14):4780-4789. PubMed

Dibirdik I, Langlie M, Ledbetter J, et al. . Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells. Blood. 1991;78(3):564-570. PubMed

Treanor LM, Zhou S, Janke L, et al. . Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med. 2014;211(4):701-713. PubMed PMC

Ribeiro D, Melão A, van Boxtel R, et al. . STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2018;2(17):2199-2213. PubMed PMC

Shochat C, Tal N, Bandapalli OR, et al. . Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208(5):901-908. PubMed PMC

Zenatti PP, Ribeiro D, Li W, et al. . Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43(10):932-939. PubMed PMC

Canté-Barrett K, Spijkers-Hagelstein JAP, Buijs-Gladdines JGCAM, et al. . MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia. 2016;30(9):1832-1843. PubMed PMC

Li Y, Buijs-Gladdines JGCAM, Canté-Barrett K, et al. . IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLoS Med. 2016;13(12):e1002200. PubMed PMC

Oliveira ML, Akkapeddi P, Alcobia I, et al. . From the outside, from within: biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia. Cell Signal. 2017;38:10-25. PubMed

Kim R, Boissel N, Touzart A, et al. . Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia. 2020;34(7):1730-1740. PubMed

Liu Y, Easton J, Shao Y, et al. . The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49(8):1211-1218. PubMed PMC

Goossens S, Radaelli E, Blanchet O, et al. . ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun. 2015;6(1):5794. PubMed PMC

Zhang J, Ding L, Holmfeldt L, et al. . The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163. PubMed PMC

Vicente C, Schwab C, Broux M, et al. . Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica. 2015;100(10):1301-1310. PubMed PMC

Meyer LK, Huang BJ, Delgado-Martin C, et al. . Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020;130(2):863-876. PubMed PMC

Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317-330. PubMed

Mendes RD, Sarmento LM, Canté-Barrett K, et al. . PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. Blood. 2014;124(4):567-578. PubMed

Milella M, Falcone I, Conciatori F, et al. . PTEN: multiple functions in human malignant tumors. Front Oncol. 2015;5:24. PubMed PMC

Zuurbier L, Petricoin EF, Vuerhard MJ, et al. . The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2012;97(9):1405-1413. PubMed PMC

Homminga I, Pieters R, Langerak AW, et al. . Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19(4):484-497. PubMed

Ferrando AA, Neuberg DS, Staunton J, et al. . Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87. PubMed

Soulier J, Clappier E, Cayuela JM, et al. . HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106(1):274-286. PubMed

Bhatla T, Jones CL, Meyer JA, Vitanza NA, Raetz EA, Carroll WL. The biology of relapsed acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2014;36(6):413-418. PubMed PMC

Loosveld M, Castellano R, Gon S, et al. . Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia (T-ALL). Oncotarget. 2014;5(10):3168-3172. PubMed PMC

Bodenmiller B, Zunder ER, Finck R, et al. . Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012;30(9):858-867. PubMed PMC

Bendall SC, Simonds EF, Qiu P, et al. . Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687-696. PubMed PMC

Bonaccorso P, Bugarin C, Buracchi C, et al. . Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: impact of PTEN exon 7 mutation on PI3K/Akt and JAK–STAT signaling pathways. Cytometry B Clin Cytom. 2020;98(6):491-503. PubMed

Dworzak MN, Buldini B, Gaipa G, et al. . AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94(1):82-93. PubMed

Watson M, Chow S, Barsyte D, et al. . The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytoametry. Cytometry A. 2014;85(1):78-87. PubMed

Mei HE, Leipold MD, Maecker HT. Platinum-conjugated antibodies for application in mass cytometry. Cytometry A. 2016;89(3):292-300. PubMed

Mei HE, Leipold MD, Schulz AR, Chester C, Maecker HT. Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry. J Immunol. 2015;194(4):2022-2031. PubMed PMC

Schulz AR, Baumgart S, Schulze J, Urbicht M, Grützkau A, Mei HE. Stabilizing antibody cocktails for mass cytometry. Cytometry A. 2019;95(8):910-916. PubMed

Chevrier S, Crowell HL, Zanotelli VRT, Engler S, Robinson MD, Bodenmiller B. Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 2018;6(5):612-620. PubMed PMC

Saeed AI, Sharov V, White J, et al. . TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34(2):374-378. PubMed

Szubert B, Cole JE, Monaco C, Drozdov I. Structure-preserving visualisation of high dimensional single-cell datasets. Sci Rep. 2019;9(1):8914. PubMed PMC

Ding J, Condon A, Shah SP. Interpretable dimensionality reduction of single cell transcriptome data with deep generative models. Nat Commun. 2018;9(1):2002. PubMed PMC

Sulis ML, Williams O, Palomero T, et al. . NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008;112(3):733-740. PubMed PMC

Silva A, Yunes JA, Cardoso BA, et al. . PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008;118(11):3762-3774. PubMed PMC

Palomero T, Sulis ML, Cortina M, et al. . Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210. PubMed PMC

Schrappe M, Valsecchi MG, Bartram CR, et al. . Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077-2084. PubMed

Dang C V., O’Donnell KA, Zeller KI, Nguyen T, Osthus RC Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253-264. PubMed

Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976-990. PubMed

Bonnet M, Loosveld M, Montpellier B, et al. . Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood. 2011;117(24):6650-6659. PubMed

Piovan E, Yu J, Tosello V, et al. . Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013;24(6):766-776. PubMed PMC

Serafin V, Capuzzo G, Milani G, et al. . Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood. 2017;130(25):2750-2761. PubMed

Delgado-Martin C, Meyer LK, Huang BJ, et al. . JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31(12):2568-2576. PubMed PMC

Ebinger S, Özdemir EZ, Ziegenhain C, et al. . Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell. 2016;30(6):849-862. PubMed PMC

Martelli AM, Lonetti A, Buontempo F, et al. . Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. Adv Biol Regul. 2014;56:6-21. PubMed

Hall CP, Reynolds CP, Kang MH. Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235. Clin Cancer Res. 2016;22(3):621-632. PubMed PMC

Coustan-Smith E, Mullighan CG, Onciu M, et al. . Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia indentified in two independent cohorts. Lancet Oncol. 2009;10(2):147-156. PubMed PMC

Basso G, Veltroni M, Valsecchi MG, et al. . Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168-5174. PubMed

Tviblindi algorithm identifies branching developmental trajectories of human B-cell development and describes abnormalities in RAG-1 and WAS patients

Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis